Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $71.09, for a total value of $71,090.00. Following the transaction, the director now directly owns 84,394 shares in the company, valued at $5,999,569.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.10, for a total value of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total value of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.59, for a total value of $262,360.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.85, for a total value of $227,400.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.36, for a total value of $507,240.00.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down 2.23% during midday trading on Thursday, reaching $68.04. The company had a trading volume of 37,615 shares. The stock’s market capitalization is $3.29 billion. The firm’s 50 day moving average price is $67.00 and its 200-day moving average price is $56.99. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.21). The firm had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The company’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same period last year, the firm earned ($1.47) earnings per share. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post ($7.08) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/agios-pharmaceuticals-inc-agio-director-lewis-clayton-jr-cantley-sells-1000-shares-of-stock/1641127.html.

Several large investors have recently made changes to their positions in AGIO. BlackRock Inc. increased its holdings in shares of Agios Pharmaceuticals by 8,463.5% in the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock valued at $126,556,000 after acquiring an additional 2,141,768 shares during the period. FMR LLC increased its holdings in shares of Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock valued at $371,846,000 after acquiring an additional 895,584 shares during the period. Vanguard Group Inc. increased its holdings in shares of Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock valued at $165,401,000 after acquiring an additional 617,379 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Agios Pharmaceuticals by 748.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock valued at $37,909,000 after acquiring an additional 572,579 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $20,423,000. Institutional investors and hedge funds own 93.97% of the company’s stock.

Several equities analysts have recently issued reports on the company. SunTrust Banks, Inc. reissued a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. J P Morgan Chase & Co reissued a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Royal Bank Of Canada assumed coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price on the stock. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $83.00 target price (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $75.20.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.